Form 4: Relay Therapeutics Director Borisy Alexis Acquires Stock Options

Director Alexis Borisy of Relay Therapeutics, Inc. acquired stock options for 102,225 shares on June 3, 2024.

Summary

• Alexis Borisy, a director of Relay Therapeutics, Inc., filed a Form 4 indicating changes in beneficial ownership.
• On June 3, 2024, Borisy acquired stock options for 102,225 shares of Relay Therapeutics common stock at an exercise price of $6.79.
• The options vest in full on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant date.
• Following the transaction, Borisy directly owns options for 102,225 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director can be seen as a sign of confidence, but it's a routine transaction.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates